DDE MRI Solutions has developed a technological platform that eliminates the use of contrast agents (gadolinium, GBS, etc.) from MRI exams, designed to detect breast (BIT-Motion) and prostate (PIT-Motion) cancer.
The patented platform consists of MRI set-up protocol and proprietary image analysis software. The platform requires no hardware and can be used with almost all existing MRI machines.
DDE's BIT-Motion system makes MRI breast exams for the detection and diagnosis of breast cancer safe, noninvasive, quick, and accurate. Using BIT-Motion for breast MRI eliminates allergic reactions, is safe for pregnant or breastfeeding patients as well as those with renal failure, and eliminates the risk of nephrogenic systemic fibrosis and deposition of the contrast material (gadolinium compounds) in the brain.
In addition, DDE can save on costs associated with contrast agents and administration (done by a physician) and shorten turnaround time by 40-50%.
The BIT-Motion system is clinically proven by hundreds of exams showing equivalence or higher accuracy in comparison with conventional contrast-enhanced MRIs.